Drug General Information
Drug ID	D09GHB
Former ID	DIB011180
Drug Name	RO-4987655
Synonyms	CH-4987655; RO-04927350; MEK inhibitors (solid tumor), Roche
Drug Type	Small molecular drug
Indication	Cancer [ICD9: 140-229; ICD10:C00-C96]		Discontinued in Phase 1	[548738]
Company	F Hoffmann-La Roche Ltd
Structure		Download 2D MOL 3D MOL
Formula	C20H19F3IN3O5
Canonical SMILES	c1c(c(c(c(c1C(=O)NOCCO)Nc1ccc(cc1F)I)F)F)CN1OCCCC1=O
PubChem Compound ID	11548630
Target and Pathway
Target(s)	MEK protein kinase	Target Info	Modulator	[544302]
KEGG Pathway	MAPK signaling pathway
	ErbB signaling pathway
	Ras signaling pathway
	Rap1 signaling pathway
	cGMP-PKG signaling pathway
	cAMP signaling pathway
	Chemokine signaling pathway
	HIF-1 signaling pathway
	FoxO signaling pathway
	Sphingolipid signaling pathway
	Oocyte meiosis
	PI3K-Akt signaling pathway
	Vascular smooth muscle contraction
	Dorso-ventral axis formation
	VEGF signaling pathway
	Osteoclast differentiation
	Focal adhesion
	Gap junction
	Signaling pathways regulating pluripotency of stem cells
	Toll-like receptor signaling pathway
	Natural killer cell mediated cytotoxicity
	T cell receptor signaling pathway
	B cell receptor signaling pathway
	Fc epsilon RI signaling pathway
	Fc gamma R-mediated phagocytosis
	TNF signaling pathway
	Long-term potentiation
	Neurotrophin signaling pathway
	Cholinergic synapse
	Serotonergic synapse
	Long-term depression
	Regulation of actin cytoskeleton
	Insulin signaling pathway
	GnRH signaling pathway
	Progesterone-mediated oocyte maturation
	Estrogen signaling pathway
	Melanogenesis
	Prolactin signaling pathway
	Thyroid hormone signaling pathway
	Oxytocin signaling pathway
	Prion diseases
	Alcoholism
	Hepatitis B
	Influenza A
	Pathways in cancer
	Proteoglycans in cancer
	MicroRNAs in cancer
	Colorectal cancer
	Renal cell carcinoma
	Pancreatic cancer
	Endometrial cancer
	Glioma
	Prostate cancer
	Thyroid cancer
	Melanoma
	Bladder cancer
	Chronic myeloid leukemia
	Acute myeloid leukemia
	Non-small cell lung cancer
	Central carbon metabolism in cancer
	Choline metabolism in cancer
PathWhiz Pathway	Fc Epsilon Receptor I Signaling in Mast Cells
	Insulin Signalling
Reactome	MAPK3 (ERK1) activation
	Uptake and function of anthrax toxins
	RAF activation
	MAP2K and MAPK activation
	Negative feedback regulation of MAPK pathway
	MAP3K8 (TPL2)-dependent MAPK1/3 activation
WikiPathways	Toll-like receptor signaling pathway
	Serotonin Receptor 4/6/7 and NR3C Signaling
	Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
	Serotonin HTR1 Group and FOS Pathway
	TCR Signaling Pathway
	ErbB Signaling Pathway
	Hypothetical Network for Drug Addiction
	Senescence and Autophagy in Cancer
	EPO Receptor Signaling
	Regulation of Actin Cytoskeleton
	IL-2 Signaling Pathway
	Insulin Signaling
	EGF/EGFR Signaling Pathway
	MAPK Cascade
	MAPK Signaling Pathway
	TGF beta Signaling Pathway
	IL-6 signaling pathway
	Signaling of Hepatocyte Growth Factor Receptor
	Kit receptor signaling pathway
	IL-3 Signaling Pathway
	Bladder Cancer
	Cardiac Hypertrophic Response
	MAP kinase activation in TLR cascade
	RAF/MAP kinase cascade
	Nanoparticle-mediated activation of receptor signaling
	Structural Pathway of Interleukin 1 (IL-1)
	Genes and (Common) Pathways Underlying Drug Addiction
	Nifedipine Activity
	PDGF Pathway
	BDNF signaling pathway
	Integrated Pancreatic Cancer Pathway
	Oncostatin M Signaling Pathway
	Corticotropin-releasing hormone
	Interleukin-11 Signaling Pathway
	AGE/RAGE pathway
	B Cell Receptor Signaling Pathway
	Prostate Cancer
	Signaling Pathways in Glioblastoma
	TSLP Signaling Pathway
	IL-9 Signaling Pathway
	Endothelin Pathways
	IL-7 Signaling Pathway
	Leptin signaling pathway
	RANKL/RANK Signaling Pathway
	IL-1 signaling pathway
	Signaling by FGFR
	Integrin-mediated Cell Adhesion
	L1CAM interactions
	MicroRNAs in cardiomyocyte hypertrophy
	Regulation of toll-like receptor signaling pathway
	Osteopontin Signaling
	IL-5 Signaling Pathway
References
Ref 548738	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028214)
Ref 544302	MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.